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We have investigated the humoral immune response to antigens of predomi-
nant gut aerobic bacterial strains (i.e. Escherichia coli) over the course of adjuvant 
arthritis and oil-induced arthritis in two inbred rat strains: Dark Agouti (DA) and 
Albino Oxford (AO). We report the presence of antibodies specifi c to proteins of E. 
coli in molecular weight range between 20–30 kDa in sera of diseased DA rats, and 
the absence of these antibodies in the sera of AO rats. In DA rats, CFA and IFA pro-
voked a stronger antibody response to E. coli, especially of the IgG2b antibody class. 
Intramuscular administration of E. coli preceding the adjuvant arthritis induction 
had no effect on the development and course of disease, as well as on the activation 
of T cells in the draining inguinal lymph nodes. Higher serum levels of natural and 
induced IgA antibodies, combined with a higher CD3+CD26+ cell percentage were 
found in AO rats. The observed correlation between the serologic response to com-
mensal fl ora and rats’ genetic background as a defi ning factor for arthritis suscepti-
bility may contribute to the process of creating a favorable (or less favorable) milieu 
for arthritis development.
Keywords: adjuvant arthritis, commensal bacteria, E. coli, humoral immune 
response, rat strains
Introduction
Autoimmune diseases are multifactorial in their etiology, therefore a myri-
ad of factors must be considered when investigating the sensitivity/resistance to 
a specifi c autoimmune disease. Although it was shown that multiple genes con-
tribute to rheumatoid arthritis (RA) susceptibility [1–4], it is believed that a com-
bination of a specifi c genetic background and some environmental factors are 
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required for the disease onset. The prevailing hypothesis involves the role of mi-
crobes and infection as possible factor s that could initiate the autoimmune pro-
cess in genetically predisposed individuals [5, 6]. In particular, numerous data 
indicate involvement of commensal microfl ora in the ethiopathogenesis of RA 
[7–9].
Adjuvant arthritis represents an animal model for rheumatoid arthritis, 
and can be induced in Dark Agouti (DA), unlike Albino Oxford (AO) strain [10]. 
We have previously shown that these rat strains show different potential to pro-
duce reactive oxygen species [11] and specifi c antibodies [12] in response to com-
mensal bacteria.
Our present study investigates if specifi c host immune response to com-
mensal bacteria could account for the differences in the development/course of 
arthritis observed in DA and AO rat strains. DA rats, unlike other rat strains, 
besides being sensitive to the induction of AA by Complete Freund-s adjuvant 
(CFA, containing Mycobacterium antigens), also develop arthritis following in-
jection of adjuvant oils without inclusion of Mycobacterium tuberculosis cell 
walls [13]. Hence, the current study examined humoral immune response to anti-
gens of predominant aerobic bacterial strains identifi ed in gastrointestinal fl ora of 
DA and AO rat strains over the course of adjuvant arthritis (AA, induced by CFA) 
and oil-induced arthritis (OIA, induced by incomplete Freund-s adjuvant, IFA). 
It appears that the predominant Gram-negative facultative aerobe in both rat 
strains is Escherichia coli, while we isolated Proteus mirabilis only from DA 
rats gut fl ora. In addition, second arm of our experiment examined whether the 
manipulation of immune response to the intestinal fl ora could infl uence the dis-
ease onset and development. In this regard animals were pre-immunized with 
their own bacterial intestinal fl ora isolate (i.e. E. coli) followed by the induction 
of adjuvant arthritis. We then determined the levels of antibodies of the specifi c 
IgM, IgG2a, IgG2b and IgA to intramuscularly encountered intestinal bacterial 
species. In addition, total number of CD3+ and CD3+CD26+ cells in inguinal 
lymph nodes, as a primarily drainage site after AA/OIA induction, was also 
 studied.
Materials and Methods
Animals
Five-month-old male rats of two inbred strains, DA (n = 40) and AO (n = 40) 
were used in experiments. DA and AO rats were derived from our laboratory’s 
inhouse breeding colony. Animals were housed in identical conventional envi-
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ronments in standard polycarbonate cages, with free access to food pellets and 
tap water. With except to bedding sterilization, no special treatment (i.e. auto-
claving, irradiation, sterilization) of the food, water, or cages for these rats was 
used. The rooms were maintained at 20 to 23 °C at humidity ranging 40% to 
70%, and under 12:12-h light:dark cycle. The experimental protocols and all pro-
cedures with animals and their care were approved by Experimental Animal 
Committee of the Institute of virology, vaccines and sera “Torlak”, and were in 
accordance with principles declared in Directive 2010/63/EU of the European 
Parliament and of the Council from 22 September 2010 on the protection of ani-
mals used for scientifi c purposes (revising Directive 86/609/EEC).
Experimental design
Experiment 1. DA (n = 5) and AO (n = 5) rats were immunized with CFA or 
IFA on day 0, and daily examined for the appearance of clinical signs of arthritis 
until day 42. Serum samples obtained on day 14 and day 42 were tested for the 
presence of anti-E. coli IgG antibodies by immunoblotting.
Experiment 2. Rats were intramuscularly pre-immunized with three doses 
of E. coli, each containing 5×108 bacterial cells, on day –21, day –14 and day 0 and 
afterwards immunized with CFA or IFA (day 0). The rats of both AO and DA 
strains were immunized with their own bacterial antigens, i.e. E. coli. The num-
ber of rats was 6 per group.
Serum levels of anti-E. coli IgM, IgG2a, IgG2b and IgA antibodies on day 
0, day 7 and day 21 were examined by ELISA. The percentages of CD3+CD26+ 
lymphocytes in inguinal lymph nodes of immunized rats (day 21) and non-immu-
nized rats were determined by fl ow cytometry. Experimental design is given in 
Table I.
Induction and assessment of arthritis
In order to induce AA, rats were immunized with a single 50 μl intra-
dermal injection of CFA (paraffi n oil 8.5 ml and Arlacel A 1.5 ml, containing 
6 mg/ml of Mycobacterium bovis, French 1173P2) in the basis of the tail. OIA was 
induced with a single 50 μl intradermal injection of IFA (paraffi n oil 8.5 ml and 
Arlacel A 1.5 ml) at the base of the tail.
Animals were daily scored for clinical signs of arthritis according to scale 
from 0 to 16, with each of four paws being scored from 0 to 4 as follows: 0 = no 
arthritic changes; 1 = oedema and/or arthritic nodules on one fi nger; 2 = oedema 
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and/or arthritic nodules on two fi ngers; 3 = oedema and/or arthritic nodules on 
three fi ngers; 4 = oedema and/or arthritic nodules on all fi ngers [14].
Bacterial preparations
Bacterial species were isolated from stool specimens collected from AO 
and DA rats. Fecal samples were collected from healthy adult rats and cultured 
using different agar plates (MacConcey agar, Endo agar) under the aerobic condi-
tions, at 37 °C for 24 h. Well-isolated colonies were selected randomly from the 
predominant fl ora and identifi ed using the Gram-staining and morphological 
characteristics, as well as the biochemical tests and a rapid identifi cation system 
(ID-32A, API Biomerieux, Marcy l’Etoile, France). E. coli was identifi ed as a 
predominant aerobic fl ora in both DA and AO rats. E. coli was grown aerobically 
for 24 h. The bacteria were harvested at stationary growth phase, washed with 
sterile phosphate-buffered saline (PBS) (8,000 rpm for 20 min), and resuspended 
in PBS. The estimated number of bacteria in the suspension was determined by 
reading the optical density at 580 nm and extrapolating the value using a standard 
curve.
Table 1. Experimental design
Experiment 1
Day 0 Day 14 Day 42
Immunizationa
CFA
IFA
Serum
(Western blot)
Serum
(Western blot)
Experiment 2
Day 21 Day 14 Day 0 Day 7 Day 21
Immunization
E. coli
E. coli
/
/
/
Immunization
E. coli
E. coli
/
/
/
Immunizationb
E. coli/CFA
E. coli/IFA
CFA
IFA
Non-immunized
Serum
(ELISA)
Serum
(ELISA)
Serum
(ELISA)
&
Lymph node cells
(Flow cytometry)
a  For each rat strain the number of animals per group was 5 
(total number of animals: DA, n = 10; AO, n = 10).
b  For each rat strain the number of animals per group was 6 
(total number of animals including non-immunized rats which were used as a control 
for fl ow cytometry analyses of lymph node cells: DA, n = 30; AO, n = 30).
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Preparation of bacterial protein extract
Following the centrifugation of bacterial culture suspension (8,000 rpm 
for 20 min), 1 g of bacterial cells pellet was homogenized on ice with the addition 
of 6 ml of extraction buffer (5% SDS, 5% 2-merkaptoethanol, 20 mM Tris, 20 
mM Glycin, 2 mM Na2EDTA, pH 6.8). The proteolysis was prevented by addition 
of protease inhibitor cocktail for mammalian tissues, P 8340 (104 mM AEBSF, 
80 μM Aprotinin, 2 mM Leupeptin, 4 mM Bestatin, 1.5 mM Pepstatin, 1.4 mM 
E-64, Sigma-Aldrich Chemie Taufkirchen, Germany) as well as 0.2 M phenyl-
methylsulphonyl fl uoride. Homogenized bacteria were centrifuged at 16,000 rpm 
for 15 min, at 4 °C; the supernatants were fi ltered through 0.45 μm fi lters, ali-
quoted into criotubes and stored at –80 °C until use.
Preparation of bacterial cell suspensions
The bacteria were killed by formalin addition (at 0.5% v/v fi nal concentra-
tion), and the suspension was held at 35 °C for more than 48 h. Cells were then 
washed three times with PBS to remove the formaldehyde, resuspended at the 
same density in sterile PBS/0.25% phenol and stored at 4 °C until use. The effi -
cacy of killing of the bacteria in the suspensions was confi rmed by sterility test. 
If no bacterial growth was detected, the formalin-inactivated bacteria were used 
as antigens for vaccines formulation and ELISA.
SDS-PAGE and Western-blot
The bacterial cells protein extracts were subjected to vertical SDS-PAGE 
according to the method of Laemmli [15] using 9% separating and 4% concen-
trating gel (0.75 mm width) on “Mini Protean II” system (BioRad Laboratories, 
Richmond, CA, USA). Gel polymerization was induced by ammoniumpersul-
phate (Pharmacia, Uppsala, Sweden) and tetramethylethylenediamine (Serva, 
Heidelberg, Germany), and the gels were blotted to nitrocellulose membranes. 
Molecular weight protein standards were obtained from BioRad Laboratories, 
Richmond, CA, USA (phosphorylase B, 94 kDa; bovine serum albumin, 67 kDa; 
ovalbumin, 43 kDa; carbon anhydrase, 30 kDa; soy-bean trypsin inhibitor, 21.1 
kDa; α-lactoalbumin, 14.4 kDa). Electrophoresis started with an initial voltage of 
30 V and next voltage step was 200 mV. The total time of electrophoresis was 30 
minutes. The proteins were detected by Coomassie Brilliant Blue staining.
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Electroforetically separated bacterial proteins were electrotransferred to 
nitrocellulose paper NC 2 (pore size of 0.2 μm, Serva, Heidelberg, Germany) as 
described elsewhere [16] using 1 mA/cm2 electricity for 1 hour 20 min at room 
temperature. Nitrocellulose membranes were incubated in blocking buffer con-
taining 1.5% skim milk (Sigma, St Louis, MO, USA) in PBS for 1 hour at 37 °C, 
followed by washing with 0.05% Tween 20 in PBS and incubation with rats sera 
diluted 1:50 in 1% bovine serum albumin (BSA), 0.1% Tween 20 in PBS for 1 
hour at room temperature. After washing, the membranes were incubated with 
the secondary antibody, anti-rat IgG-alkaline phosphatase (Sigma, St Louis, MO, 
USA) for 1 hour at room temperature and stained by addition of the substrate 
5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (Sigma, St Louis, 
MO, USA). The reaction was stopped with the distilled water and blots were 
dried at room temperature and photographed.
ELISA
Formalin-inactivated bacterial cells (E. coli) were adsorbed separately to 
microtiter plates, using 50 μl per well at the concentration of 1×108 bacterial cells 
per ml. After one centrifugal cycle (1,700 rpm for 15 min) and an additional incu-
bation at 37 °C for 1 hour, the plates were washed and saturated with 200 μl/well 
of 1% BSA/PBS. The sera were diluted in 1% BSA/PBS and incubated overnight 
at 4 °C. The binding of rat serum antibacterial antibodies was detected using the 
secondary antibodies specifi c for rat Ig individual isotypes, labeled with biotin. 
Extravidine-peroxidase and substrate o-phenylene diamine (Sigma, St Louis, 
MO, USA) were used for detection. The optical density (OD) was measured pho-
tometrically at 492/620 nm. For the anti-bacterial IgM, IgG2a and IgG2b deter-
mination, the sera were diluted 1:400, while the IgA antibodies specifi c for bac-
teria were detected in sera diluted 1:50.
Immunolabeling and fl ow cytometry analysis
The inguinal lymph nodes were isolated from both non-immunized and 
immunized rats. Individual cell suspensions were adjusted to 1×107 cells/ml and 
100 μl of each cell suspension was labeled with anti-CD3-biotin antibody (Clone 
G4.18) followed by Streptavidin-FITC and anti-CD26-PE antibody (Clone OX-61). 
All antibodies were purchased from BD Pharmingen (San Diego, CA, USA). 
 Immunolabeling was performed at 4 °C for 30 minutes. Samples (a total of 1×104 
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fl ow cytometric events) were analyzed on a FACScan fl ow cytometer (Cell Quest 
software, Becton Dickinson).
Statistical analysis
The quantitative data obtained were analyzed by two-factor ANOVA: 
strain (DA, AO) × time (day 0, day 7, day 21) for the levels of anti-E. coli antibod-
ies; and strain (DA, AO) × immunization (CFA, IFA, E. coli/CFA, E. coli/IFA) for 
the changes in the percentage of CD3+CD26+ cells in inguinal lymph nodes, fol-
lowed by Bonferroni as post-hoc test if appropriate. Strain differences in the per-
centages of CD3+ and CD3+CD26+ cells in the lymph nodes of non-immunized 
rats were determined by Student’s t-test. A p value of less than 0.05 was consid-
ered signifi cant. All analyses were performed by GraphPad PRISM-version 5.
Results
Clinical signs of arthritis following the immunization with CFA and IFA
Animals of both strains were examined daily for the appearance of clinical 
signs of arthritis on fore leg paws and hind paws for 42 days post immunization 
with CFA and IFA. In DA rats clinical signs of arthritis appeared on day 13 and 
day 15 following immunization with CFA and IFA, respectively, and all rats re-
covered by day 34 (Fig. 1A). Intense foot swelling was accompanied by frequent 
arthritic nodules in DA rats immunized with CFA, while immunization with 
IFA induced lower grade fi nger edema in two animals and no clinical signs of 
arthritis in three animals (Fig. 1B). The incidence of clinical signs of arthritis is 
shown in Figure 1C. Clinical signs of arthritis were not observed in AO rats im-
munized with CFA or IFA
Humoral immune response to E. coli following 
the immunization with CFA and IFA
We have shown previously the presence of anti-E. coli IgG antibodies in 
the sera of non-immunized rats of both DA and AO strains, and this IgG priming 
was observed against a limited repertoire of E. coli proteins [12]. In order to 
monitor the immune response to E. coli during inductive phase of arthritis, the 
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Figure 1. Clinical signs of arthritis (mean±SEM). (A), individual maximum clinical sign 
and corresponding means (B), and the incidence of clinical signs (C) in DA and AO rats following 
immunization with CFA or IFA. The number of rats was 5 per group
sera obtained on day 14 after immunization with CFA and IFA were examined 
for the presence anti-E. coli IgG antibodies by immunoblot.
On day 14 after immunization with IFA and CFA very weak anti-E. coli 
IgG binding levels were detected in sera of AO rats (Fig. 2A). Conversely, anti-
bodies against E. coli proteins of molecular mass ~28 kDa were found in DA rats, 
which were immunized with CFA and developed signs of disease (Fig. 2A). Fol-
lowing complete recovery from the arthritis, a signifi cant drop in IgG binding to 
E. coli protein extracts was observed in DA rats (day 42), while the sera of AO 
rats continued to show no signifi cant reactivity (Fig. 2B).
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Figure 2. Western blot analysis of IgG binding to E. coli proteins in sera of AO and DA rats 
immunized with CFA and IFA on day 14 (A) and day 42 (B). Sphere contour highlights bands 
for IgG antibodies recognizing E. coli proteins of molecular mass ~28 kDa
The effect of pre-immunization with E. coli on humoral immune response 
to E. coli following the immunization with CFA and IFA
Anti-E. coli antibodies of all classes were detected in the sera obtained on 
day 0 in all experimental groups of DA and AO rats (Fig. 3). Before immuniza-
tion with CFA or IFA (day 0) animals from groups E. coli/CFA and E. coli/IFA 
already had high levels of serum IgM, IgG2a and IgG2b class antibodies specifi c 
for E. coli, while the level of IgA antibodies was considerably lower. As expected, 
animals that were immunized with E. coli, and then received CFA or IFA, had 
signifi cantly higher levels of antibodies of all three classes compared to animals 
that received only CFA or IFA, at all time points tested. By contrast, marked dif-
ferences were observed in anti-E. coli IgM, IgG2a, IgG2b and IgA antibody lev-
els between the two rat strains following the specifi ed treatments. Not taking into 
account the absolute value of the level of antibodies, there are noticeable trends 
in the kinetics of antibody production between the strains. The sera of DA rats 
contained almost twice the level of antibodies (IgM, IgG2a, IgG2b) compared to 
the AO strain. The differences were even more pronounced between the strains’ 
IgG2a and IgG2b antibodies classes on day 7 and day 21. On the other hand, the 
specifi c antibody levels in AO rats’ sera did not signifi cantly change during the 
observed period. IgA antibodies were detected at low values, but were at a higher 
level in AO rats strain when compared to DA rats. Statistical analyses of anti-
 E. coli antibody levels within particular subclass of antibody revealed signifi cant 
interaction of factors, strain × time (p values for the interaction are shown in the 
graphs, Fig. 3). Similar changes in the level of IgA antibodies following immuni-
zation were observed in E. coli/IFA group of DA and AO rats. Namely, the level 
of IgA antibodies rise on day 7 and decline on day 21 in both rat strains (the sig-
nifi cant main effect of time, p < 0.001). However, at all time points examined, the 
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level of these antibodies was higher in AO rat’s sera in comparison with DA rats 
sera (the signifi cant main effect of strain, p < 0.001).
The effect of pre-immunization with E. coli on T lymphocytes activation 
in inguinal lymph nodes from rats immunized with CFA or IFA
No strain difference in proportion of CD3+ cells in the lymph nodes of non-
immunized rats was observed (Fig. 4A). However, non-immunized AO rats ex-
hibited higher percentage of CD3+CD26+ cells in the inguinal lymph nodes in 
comparison with non-immunized DA rats, p < 0.001 (Fig. 4B). Consequently, the 
strain difference in the activation of CD3+ lymphocytes following different regi-
ments of immunization was estimated by the change of the percentage of 
CD3+CD26+ cells relative to non-immunized control of each strain. Immuniza-
tion with CFA or IFA increased the percentages of CD3+CD26+ cells in inguinal 
lymph nodes of DA rats regardless of the pre-immunization with E. coli (Fig. 4C). 
On the contrary, decreased percentages of CD3+CD26+ cells were observed in 
Figure 3. Anti-E. coli antibody levels of IgM, IgG2a, IgG2b and IgA isotypes in sera of DA 
(black squares) and AO (white circles) rats immunized with CFA, IFA, E. coli/CFA or E. coli/IFA 
on day 0, day 7 and day 21, quantifi ed by ELISA. The number of sera samples was 6 per group. 
The results are expressed as OD492×1000 (mean + SD). P value for the statistically signifi cant interaction 
of factors (strain × time) is shown in the top right corner of each graph
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inguinal lymph nodes of immunized AO rats when compared to corresponding 
non-immunized control. Statistical analyses of the percentages of change of 
CD3+CD26+ cells following immunization revealed signifi cant interaction of 
 factors, strain × treatment, p < 0.001 (Fig. 4C).
Discussion
The fi ndings published earlier speculated about the possible involvement of 
E. coli in pathogenesis of RA, primarily due to cross-reactivity between the pep-
tide sequences present in its Heat shock protein (Hsp), DnaJ protein and the se-
Figure 4. The percentages of CD3+ cells (A) and CD3+CD26+ cells (B) in inguinal lymph nodes 
of non-immunized DA and AO rats. Changes in the percentage of activated CD3+CD26+ cells 
in inguinal lymph nodes of rats immunized with CFA, IFA, E. coli/CFA or E. coli/IFA 
on day 21 relative to non-immunized control (C). The results are expressed as mean + SEM. 
The number of animals was 6 per group. Statistically signifi cant differences: 
***p < 0.001, t-test; and p < 0.001, interaction of factors (strain × immunization), two-factor ANOVA
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quences that were associated with susceptibility to RA [17]. However, no in-
creased levels of anti-E. coli antibodies were found in patients compared to 
healthy individuals in numerous studies. Newkirk et al. reported the increased 
levels of IgM antibodies to E. coli in early rheumatoid factor-positive RA [18]. 
Following immunization with CFA and IFA, we have detected anti-E. coli anti-
body of IgG class in sera of both DA and AO rats, which differed in respect to 
their specifi city, quantity and kinetics. Specifi cally, the presence of antibodies 
specifi c for the protein of molecular weight of ~28 kDa in sera of DA rats immu-
nized with CFA suggested its association with the experimental arthritis.
It is well established that Hsps are the prominent targets of the immune 
response during the course of experimental arthritis. Bacterial heat shock pro-
teins, primarily Hsp60 have been shown to be highly immunogenic mole-
cules, able to activate a large number of T-cells. Hsp60 and Hsp70 recognition by 
T-cells and antibodies was implicated in numerous autoimmune infl ammatory 
diseases [19].
It was shown that E. coli heat shock proteins, GroEL (molecular weight of 
60 kDa) and GroES (molecular weight about 15 kDa) could act jointly to form the 
so-called GroE complex, twisting and help protein folding end protein subunits 
[20].
Our results point out that IgG antibodies to proteins of molecular weights 
60 kDa and 15 kDa were not present in sera of our experimental rats. Even though 
we have used the whole E. coli protein extract and not the individual purifi ed 
components such as a specifi c Hsp in our assays, the involvement of other Hsps 
cannot be excluded. It is recognized that both prokaryotic and eukaryotic cells 
produce a group of proteins with molecular mass of 15 to 42 kDa, designated 
as small heat shock proteins (sHsp) [21]. Some data are available supporting 
the proposal that disparate immune responses to Hsp are involved in different 
phases of arthritic disease [22]. It would certainly be important to investigate 
whether these antibodies may be regarded as diagnostic markers of arthritis or if 
they could also have a more prominent role, exhibiting a modulatory effect on 
the disease.
In the aim to further investigate humoral immune response to selected 
 antigens of commensal fl ora, we decided to immunize animals with their own 
E. coli, and then induce the disease. It should be noted that pre-immunization 
with E. coli did not infl uence the incidence and the clinical signs of arthritis as-
sessed until day 21 after immunization with CFA and IFA (data not shown) in 
DA rats, while none of AO rats developed the arthritis. Literature data show that 
the exposure of mice/rats to certain bacteria can actually induce protection from, 
rather than development of a disease. It has been shown that E. coli can render 
germ-free rats resistant to subsequently induced AA [23]. Also, accumulating 
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evidence suggests that resistance to AA was due to the protective effect of anti-
bodies specifi c for some Hsps. Ulmansky et al. concluded that Hsp, besides con-
taining pathogenic T cell epitopes in AA, also contains protective B cell epitopes 
exposed on its surface, and that natural and acquired resistance to AA is associ-
ated with the ability to respond to these epitopes [24]. In this case, it would sug-
gest a possibility that our genetically susceptible DA rat strain is unable to re-
spond to protective epitopes adequately. Another possible reason is the very 
nature of bacterial antigen used. It has been reported that Hsp, including minor 
subfamilies could protect against arthritis, whereas some other conserved bac-
terial proteins do not [25]. At last, the route of administration of potentially pro-
tective immunogen seems to be very important. Cobelens et al. reported that oral 
treatment with Hsp65 during the ongoing disease signifi cantly reduced the ac-
tivity of adjuvant-induced arthritis [26].
When examining the levels and strain distribution of different classes of 
antibodies we have discovered high production of E. coli-specifi c antibodies pri-
marily in DA rats. Namely, the sera of diseased DA rats contained much higher 
levels of antibodies (IgM, IgG2a, IgG2b) compared to the AO strain. These fi nd-
ings are the extension of results in our previous work (without arthritis induction) 
which pointed out that immune response to own E. coli in AO rats refl ected in 
weaker antibody production in combination with higher CD3+ cells proliferation 
compared to DA rats are indicative of suppressive immune mechanisms directed 
to these bacterial antigens.
Higher production of E. coli-specifi c antibodies in DA rats coincided with 
the peak of the disease (day 21) and were predominantly of IgG2b class in the rat 
immune system IgG1 and IgG2a antibodies are associated with a Th2-type re-
sponse, while the IgG2b subclass is associated with a Th1-type response [27–29]. 
While the CFA and IFA were causing comparable levels of IgG2a and IgG2b E. 
coli-specifi c antibodies, suggesting mixed Th1/Th2 type of immune response, 
the pre-immunization with E. coli skewed the immune response toward promot-
ing the Th1-like response pattern.
This fi nding suggests the need for more detailed insight into the specifi c 
alterations of the immune response caused by IFA and CFA. It is generally 
 accepted that the CFA and IFA act to form a depot at the injection site, thus pro-
longing the duration of release of the antigen and its interactions with antigen 
presenting cells. Thereby they provide a complex set of signals for non-specifi c 
branch of the immune system, resulting in altered cell proliferation and differen-
tiation of leukocytes. The effects of IFA/CFA include a fast uptake of adjuvant 
components by the dendritic cells, enhanced phagocytosis, secretion of cy-
tokines by mononuclear phagocytes, and passing the activation and proliferation 
of CD4+ lymphocytes. In models where administration of IFA or CFA causes 
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autoimmune disease in absence of intentionally added autoantigen, i.e. AIA and 
OIA (as used in our work), the polyclonal activation of lymphocytes is probably 
the crucial event [30]. In case of CFA, the cross-reactivity of antimycobacterial 
antibodies or T-cell receptors with epitopes of host proteins is considered the 
most probable mechanism. On the other hand, the ability of oil adjuvant to induce 
the disease could be attributed to breaking of peripheral tolerance and activation 
of constitutively present arthritogenic T-cell clones [30]. Activated T lympho-
cytes produce sets of different lymphokine combinations specifi c for type 1 or 
type 2 helper activity; while the immunization with IFA favors Th2, the immuni-
zation with CFA favors Th1 responsiveness [31]. In our experiments, the immu-
nization with CFA and IFA caused the increase in production of anti-E. coli 
 antibodies of  IgG2a and IgG2b classes, respectively. Clearly, a very complex 
mechanism underlying the pathogenesis of adjuvant arthritis creates the environ-
ment in which the disregulation of cytokine profi le infl uenced the humoral im-
mune response we measured. In any case, further understanding of the CFA and 
IFA mode of action in induction of adjuvant arthritis is needed to be able to un-
ambiguously defi ne key elements in the onset and disease development.
The role of CD26/DPIV in autoimmune diseases has been widely studied. 
The increased number of peripheral T cells expressing CD26 was demonstrated 
in RA patients [32]. On the other hand, in plasma of RA patients the activity of 
this enzyme as antigen CD26 was decreased, as well as in plasma of animals with 
experimental arthritis [32]. Reduced levels of CD26 are associated with the se-
verity of infl ammation. However, other studies have shown that pharmacological 
inhibition of this enzyme stops the progression of the disease. Moreover, a num-
ber of in vitro and in vivo studies have used inhibitors of this molecule, highlight-
ing CD26/DPIV as a potential target for the immunosuppressive therapy [33, 34]. 
The relative role of CD26 in RA is not yet apparent. It is unclear whether the 
level of this enzyme may affect infl ammation over the course of RA, or whether 
the expression of this enzyme may be decreased in infl ammatory arthritis.
In our study non-immunized animals of both rat strains, exhibited approx-
imately equal numbers of CD3+ cells in the inguinal lymph nodes, but the number 
of CD3+CD26+ cells was signifi cantly higher in AO rats. The difference can be 
explained by their genetic background, which is signifi cantly different in terms of 
expression of CD26 molecules. In general, the ability of T cells to regulate the 
level of membrane CD26 expression seems to be a specifi c feature of T cells, and 
is not observed with endothelial and renal cells, where CD26 is constitutively 
produced and its membrane level is relatively constant. This suggests that the 
location can be critical, and that locally present peptides can be sensitive to deg-
radation by CD26/DPIV expressed on T-cells [35]. In our case, it could mean that 
the inguinal lymph nodes of AO rats provide a favorable milieu for active degra-
 ESCHERICHIA COLI AND ADJUVANT ARTHRITIS 15
Acta Microbiologica et Immunologica Hungarica 62, 2015
dation of bioactive mediators; vice versa, the reduced numbers of CD3+CD26+ 
found in DA rats may be responsible for the autocrine defect in degradation of 
these mediators. Furthermore, it was shown that proteins and peptides that are 
part of the repertoire of biological constituent associated with CD26/DPIV can 
function as DPIV inhibitors in mice [36]. Several reports emphasize the impor-
tance of this marker as an inhibitory receptor that can serve as a target for ligands 
that block the enzyme activity and inhibit T cell activation and Th1-mediated 
immunity [33].
Immunization with CFA and IFA or pre-immunization with E. coli did not 
affect the percentage of T cells expressing CD26 in DA rats compared to intact 
animals. The percentage of positive cells was determined in the inguinal lymph 
nodes isolated on day 21 after immunization. It is possible that the percentage of 
positive cells would differ between the groups in other time points. It is well es-
tablished that the expression of pro-infl ammatory cytokines (TNF, IFN-γ, IL-2 
and IL-17) increases in the inguinal lymph nodes in the early stages of AA [37]. 
The expression of these cytokines is transient, with the exception of IFN-γ, show-
ing secondary growth later in the course of the disease (from day 17 onwards). 
Also, it was suggested that the initial increase in IFN-γ occurs within pro-infl am-
matory response and that the subsequent increase may refl ect the activation of 
regulatory T cells [37]. Thus, it is possible that even at the peak of the disease, 
a signifi cant change in the population of T cells might be taking place; it is only 
that within the limited time period available we might have missed the narrow 
window of opportunity to detect these subtle differences between the experi-
mental groups.
In AO rats, immunization with CFA decreased the percentage of 
CD3+CD26+ cells relative to non-immunized control, whereas pre-immunization 
with E. coli diminished it only in comparison with animals immunized with 
IFA. These results can be viewed in light of the fact that CD26 expression in-
creases after T cell activation [38] and continues to play a critical role in enabling 
the activated T cell to move into the extravascular space and consequently to 
the place of infl ammation. Since AO rats are the arthritis resistant strain, we 
would like to suggest a possibility that, among other, this mechanism could con-
tribute to prevention of infl ammatory lesions in this strain.
Conclusion
Taken together, antibodies against E. coli proteins of molecular mass 
~28 kDa were found in DA rats after immunization with CFA and IFA, during the 
inductive phase of arthritis. Following resolution of the disease, the examined 
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sera have shown no signifi cant reactivity to E. coli proteins. Also, CFA and IFA 
caused high production of IgM, IgG2a and IgG2b anti-E. coli antibodies in DA 
rats, which coincided with the peak of the disease and immunization with 
own E. coli enhanced this effect. On the other hand, the pre-immunization with 
E. coli did not infl uence the incidence and the clinical signs of arthritis, as well as 
the activation of T cells in the draining inguinal lymph nodes of DA rats.
Generally, elevated level of antibodies to E. coli antigens, as a hyper-re-
sponsive immunological response to examined bacteria was found in arthritis-
susceptible DA rats and not in arthritis-resistant AO rats. The correlation be-
tween serologic response to commensal fl ora and susceptible rat’s genetic 
background may contribute to the marked differences in the immune reactivity 
of AO and DA rats and may be of signifi cance in further understanding of the role 
of humoral immunity in the pathogenesis of autoimmune arthritis. Our results 
suggest that, at least in DA rats, basal and immunization-induced elevated 
 immune response to E. coli antigens, although not decisive for disease suscepti-
bility, probably represents a priming factor that sets a scene for subsequent im-
mune events leading to a predisposition to arthritis induction.
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